NeuroHagana

Preventing Permanent Disabilities after Neurotrauma

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in March 2023 by Angela Ruban, NeuroHagana operates with 1–10 employees. The company is currently in the Pre-Funding stage and was selected for the SCI Incubate 2025 Cohort by the Praxis Spinal Cord Institute in May 2025.

Business overview

NeuroHagana develops an injectable emergency treatment designed to prevent permanent disabilities following neurotrauma, regardless of its type or severity. The company's novel technology focuses on immediately protecting against Glutamate Excitotoxicity, a primary factor in neurotrauma pathology. This treatment has been pre-clinically validated in animal models for Spinal Cord Injury, Traumatic Brain Injury, and Athletes Concussion without side effects. NeuroHagana aims to serve markets in Europe and the USA, with initial applications targeting Spinal Cord Injury, and later expanding to Traumatic Brain Injury and Stroke, positioning its product as a vital component for paramedics, hospital trauma units, first aid teams, and military forces.

Strategic signal

In May 2025, NeuroHagana was selected for the SCI Incubate 2025 Cohort by the Praxis Spinal Cord Institute. This selection signals significant validation for NeuroHagana's innovative neurotrauma treatment, highlighting its potential impact within the spinal cord injury community and attracting further attention from investors and strategic partners in the health tech and life sciences sector.

Company Intelligence Q&A

What is NeuroHagana's core focus?
NeuroHagana focuses on developing an injectable emergency treatment to prevent permanent disabilities after neurotrauma by addressing Glutamate Excitotoxicity.
When was NeuroHagana founded?
NeuroHagana was founded in March 2023.
Who is a key founder of NeuroHagana?
Angela Ruban is a Co-founder and CEO of NeuroHagana.
What is the current employee size of NeuroHagana?
NeuroHagana currently has 1–10 employees.
What significant recognition did NeuroHagana receive in May 2025?
In May 2025, NeuroHagana was selected for the SCI Incubate 2025 Cohort by the Praxis Spinal Cord Institute.

External links